121O RATIONALE 309: A randomized, global, double-blind, phase III trial of tislelizumab (TIS) vs placebo, plus gemcitabine + cisplatin (GP), as first-line treatment for recurrent/metastatic nasopharyngeal cancer (RM-NPC)

Yunpeng Yang, Jingxue Pan, Hao Wang, Shenhong Qu, N. Chen, X. Chen, Yan Sun, Xiaohui He, Chaosu Hu, Lizhu Lin, Qitao Yu, Siyan Wang, G. Wang, F. Lei, Ji Wen, Kunyu Yang, Zhixiong Lin, Yue Wu, Wenfeng Fang, L. Zhang